ClinicalTrials.gg
RecruitingNCT07075679AI-BCSQUpdated Apr 2, 2026

Screening Mammography: Single Reading by One Radiologist With AI vs. Double Reading by Two Radiologists (AI-BCSQ)

An interventional study of Group with AI iCAD version 3 and Group without AI in Breast Cancer Screening, Artificial Intelligence (AI) and Breast Cancer Screening and Diagnosis, sponsored by University Hospital Olomouc. Recruiting at 1 site in Czechia. Open to female participants aged 45 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Primary conditionBreast NeoplasmsRegistry: DiseaseReclassifiedWhy we changed it
Registry
Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Breast Neoplasms
Why
  1. Disease describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital Olomouc · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8,000
Allocation
Randomized
Ages
45 Years to 69 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 177 studies in Breast Neoplasms with a site in Czechia — 21 open to participants now, 44 under way, 31 of them phase 3. Breast Neoplasms · Czechia.

Planned enrollment
2nd of 161
8,000 · median 500
Started
2025
with 13 others
No phase
9 of 177
4 open now
Primary completion
2028-10
later than 32 of 43 live
Registered
168th of 177
by date

Among the 177 studies in Breast Neoplasms with a site in Czechia, this one is the 2nd largest by planned enrollment of the 161 interventional ones that give a count, is one of 14 that started in 2025, is one of 9 with no phase, reaches primary completion later than 32 of the 43 other live ones, and was the 168th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

21 of the 177 studies in Breast Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 45 Years to 69 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Breast Neoplasms with a site in Czechia, or all of them as a file.
02

Study summary

A randomized prospective study comparing the evaluation of mammography images in a breast cancer screening programme by a single radiologist with AI support versus standard double reading by two radiologists without AI support.

Read the detailed description

In the intervention group, the first reading of the screening mammogram will be performed by one radiologist with AI support. After this AI-assisted first reading is completed and recorded for the study, a standard second reading will be carried out by another radiologist. This ensures that the legal requirement for double reading in the breast cancer screening program is maintained.

In the control group, mammograms will be evaluated according to the current standard practice - that is, independently by two radiologists without AI support.

Participants will be divided to the two groups based on a randomization scheme that determines specific days for evaluation with AI (Group 1) and without AI (Group 2). The randomization ensures equal distribution of weekdays between the two groups to minimize bias due to variability in daily workflow, diagnostic/screening ratios, or other operational factors.

03

Conditions studied

  • Breast Cancer Screening
  • Artificial Intelligence (AI)
  • Breast Cancer Screening and Diagnosis

Browse trials for

Keywords

  • breast cancer
  • screening
  • artificial intelligence
04

In context

Breast Neoplasms Reclassified

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 8,000 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University Hospital Olomouc is the lead sponsor of 40 studies on the registry; 13 are open to participants now.

Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 45-69, asymptomatic woman participating in breast cancer screening programme

Exclusion criteria

Exclusion Criteria:

  • clinical signs of breast disease - indication for diagnostic mammography
06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,000 participants (estimated)

Study arms

  • Experimental
    Group with AI

    Asymptomatic women aged 45-69 participating in breast cancer screening programme, reading of mammograms by one radiologist with AI support.

    Diagnostic Test: Group with AI iCAD version 3

  • Other
    Group without AI

    Asymptomatic women aged 45-69 participating in breast cancer screening programme, reading of mammograms by two radiologists without AI (current practice).

    Diagnostic Test: Group without AI

Interventions

  • Diagnostic testGroup with AI iCAD version 3

    Reading mammograms by one radiologist with AI support

  • Diagnostic testGroup without AI

    Standard double reading by two radiologists without AI.

07

What researchers measure

Primary outcomes

  1. Further assessment rate

    The proportion of women udergoing follow-up examinations within 0-190 days after screening mammography.

    Time frame: up to 190 days after screening mammmography

Secondary outcomes

  1. Cancer Detection Rate

    The number of cancers detected per 1,000 women screened.

    Time frame: up to 1 year after screening mammography

  2. Recall Rate

    The proportion of women recalled for follow-up examinations withing 1-190 days after screening mammography.

    Time frame: up to 190 days after screening mammography

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Larsen M, Olstad CF, Lee CI, Hovda T, Hoff SR, Martiniussen MA, Mikalsen KO, Lund-Hanssen H, Solli HS, Silberhorn M, Sulheim AO, Auensen S, Nygard JF, Hofvind S. Performance of an Artificial Intelligence System for Breast Cancer Detection on Screening Mammograms from BreastScreen Norway. Radiol Artif Intell. 2024 May;6(3):e230375. doi: 10.1148/ryai.230375. PubMed 38597784 ↗
  • Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017 Dec;14(12):749-762. doi: 10.1038/nrclinonc.2017.141. Epub 2017 Oct 4. PubMed 28975929 ↗
  • Tudos Z, Veverkova L, Baxa J, Hartmann I, Ctvrtlik F. The current and upcoming era of radiomics in phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2025 Jan;39(1):101923. doi: 10.1016/j.beem.2024.101923. Epub 2024 Aug 23. PubMed 39227277 ↗
  • McDonald ES, Conant EF. Can AI Reduce the Harms of Screening Mammography? Radiol Artif Intell. 2023 Oct 25;5(6):e230304. doi: 10.1148/ryai.230304. eCollection 2023 Nov. No abstract available. PubMed 38074781 ↗
  • Letter H, Peratikos M, Toledano A, Hoffmeister J, Nishikawa R, Conant E, Shisler J, Maimone S, Diaz de Villegas H. Use of Artificial Intelligence for Digital Breast Tomosynthesis Screening: A Preliminary Real-world Experience. J Breast Imaging. 2023 May 22;5(3):258-266. doi: 10.1093/jbi/wbad015. PubMed 38416890 ↗
  • Dahlblom V, Dustler M, Tingberg A, Zackrisson S. Breast cancer screening with digital breast tomosynthesis: comparison of different reading strategies implementing artificial intelligence. Eur Radiol. 2023 May;33(5):3754-3765. doi: 10.1007/s00330-022-09316-y. Epub 2022 Dec 11. PubMed 36502459 ↗
  • Eisemann N, Bunk S, Mukama T, Baltus H, Elsner SA, Gomille T, Hecht G, Heywang-Kobrunner S, Rathmann R, Siegmann-Luz K, Tollner T, Vomweg TW, Leibig C, Katalinic A. Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. Nat Med. 2025 Mar;31(3):917-924. doi: 10.1038/s41591-024-03408-6. Epub 2025 Jan 7. PubMed 39775040 ↗
  • Diaz O, Rodriguez-Ruiz A, Sechopoulos I. Artificial Intelligence for breast cancer detection: Technology, challenges, and prospects. Eur J Radiol. 2024 Jun;175:111457. doi: 10.1016/j.ejrad.2024.111457. Epub 2024 Apr 16. PubMed 38640824 ↗
  • Lang K, Dustler M, Dahlblom V, Akesson A, Andersson I, Zackrisson S. Identifying normal mammograms in a large screening population using artificial intelligence. Eur Radiol. 2021 Mar;31(3):1687-1692. doi: 10.1007/s00330-020-07165-1. Epub 2020 Sep 2. PubMed 32876835 ↗
  • Lang K, Josefsson V, Larsson AM, Larsson S, Hogberg C, Sartor H, Hofvind S, Andersson I, Rosso A. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncol. 2023 Aug;24(8):936-944. doi: 10.1016/S1470-2045(23)00298-X. PubMed 37541274 ↗
  • Dembrower K, Crippa A, Colon E, Eklund M, Strand F; ScreenTrustCAD Trial Consortium. Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. Lancet Digit Health. 2023 Oct;5(10):e703-e711. doi: 10.1016/S2589-7500(23)00153-X. Epub 2023 Sep 8. PubMed 37690911 ↗
  • Chang YW, Ryu JK, An JK, Choi N, Park YM, Ko KH, Han K. Artificial intelligence for breast cancer screening in mammography (AI-STREAM): preliminary analysis of a prospective multicenter cohort study. Nat Commun. 2025 Mar 6;16(1):2248. doi: 10.1038/s41467-025-57469-3. PubMed 40050619 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 35 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 35 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 20, 2025
StartActual
Oct 6, 2025
Primary completionEst.
Oct 5, 2028
CompletionEst.
Oct 5, 2028
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07075679
Lead sponsor
University Hospital Olomouc
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Oct 6, 2025
Primary completion
Oct 5, 2028 (estimated)
Completion
Oct 5, 2028 (estimated)
Last update
Apr 2, 2026

Study contacts

Lucia Veverkova, MD
Contact
lucia.veverkova@fnol.cz
+420603181913

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion